You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Because of COVID-19, the San Diego-based firm said it was unable to ship new instruments and many users were unable to operate their existing ones.
The San Diego-based genomic analysis firm reported $3.3 million in revenue, driven by growth in North America sales, offset by a decline in international sales.
The firm's cytogenetic media, immunohistochemistry products, and fish probes have been certified for marketing in Europe.
A genomics researcher from North Carolina State University outlined efforts to learn more about human cancers by studying dogs and other animals with spontaneous malignancies.
Some geneticists who use arrays hope the new guidelines, which ACMG updated this month, will prompt other labs to adopt the technology and compel insurance firms to reimburse for the tests.
According to CEO Kevin King, Affy's "efforts to prepare the company for renewed revenue growth and profitability … have started to pay off."
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.